GoldenGolden
Advanced Search
Clover Biopharmaceuticals

Clover Biopharmaceuticals

A clinical stage biopharmaceutical company in R & D and the industrialization of innovative drugs and high-end biological similar drugs. Clover Biopharmaceuticals is focused on tumor treatment and autoimmune diseases.

Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars. Trimer-Tag allows the production of covalently trimerized fusion proteins to target trimerization-dependent pathways such as the tumor necrosis factor (TNF) superfamily and the enveloped RNA virus proteins that allow the virus to gain entry into host cells.

COVID-19 response

Clover Biopharmaceuticals generated a trimeric Spike-protein (S-Trimer) subunit vaccine candidate for the new coronavirus causing the COVID-19 outbreak. Like other coronaviruses, the COVID-19 coronavirus strain has a trimeric spike (S) protein on the viral envelope that enables the virus to attach to the host cells surface receptor ACE2 and gain entry into the cell. A mammalian cell expression system was used to produce the trimeric Spike-protein. It is an antigen recognized by antibodies in the sera of patients fully recovered from the new coronavirus, which suggests that as a vaccine the Spike-protein trimer could serve as a vaccine by triggering a protective immune response. The vaccine development included partnership with Chengdu Hi-Tech Park and Chengdu Center for Public Health teams. Clover has partnered with GlaxoSmithKline (GSK) in further development of their Covid-19 S-Trimer vaccine candidate. GSK will supply its pandemic adjuvant system for preclinical studies. An adjuvant can reduce the amount of vaccine protein required.

Timeline

July 7, 2020
Clover Biopharmaceuticals raises a $24,000,000 series B round from GL Ventures.
June 8, 2020
Clover Biopharmaceuticals raises a $24,000,000 series B round from GL Ventures.
November 27, 2019
Clover Biopharmaceuticals raises a $43,304,843 series B round from Betta Biomedical Industry Fund, Delos Capital, Jinlong Group, Lapam Capital, Sichuan Province Healthy Pension Industry Equity Investment Fund and Zhongguancun VC Development Center.
December 14, 2017
Clover Biopharmaceuticals raises a $950,075 series A round from Tianhe Life Sciences Venture Fund.

Funding rounds

People

Name
Role
LinkedIn

Jianwei Zhu

Co-Founder

Peng Liang

Co-Founder, President

Xiaodong Wang

Co-Founder

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Nick Paul
September 22, 2021
FierceBiotech
Clover Biopharmaceuticals' bid to help vaccinate the world against COVID-19 has taken a big step forward. The adjuvanted protein vaccine SCB-2019 held up against a range of variants in a phase 2/3 trial, teeing Clover up to seek approval of the relatively stable jab and deliver it to the COVAX Facility.
Brandon May
May 18, 2021
BioSpace
Temasek has committed $200 million to launch The G2 Bio Companies which focuses on the development of potential next-generation gene therapies.
BioSpace
May 17, 2021
BioSpace
Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company committed to developing novel vaccines and biologic therapeutic candidates to address the world's most life-threatening diseases and public health threats, today announced positive preclinical data from its second-generation, protein-based COVID-19 vaccine candidate, a modified B.1.351 Spike (S)-Trimer
Clover Biopharmaceuticals
May 18, 2021
www.prnewswire.com:443
The publication is available as a pre-print on bioRxiv Preclinical data demonstrates that a modified B.1.351 S-Trimer vaccine candidate induces broad...
Nick Paul
February 23, 2021
FierceBiotech
Clover Biopharmaceuticals has raised $230 million to take a COVID-19 vaccine candidate into a phase 2/3 clinical trial. The series C positions the Chinese biotech to validate the efficacy of its vaccine and gear up to manufacture hundreds of millions of doses this year.
Clover Biopharmaceuticals
February 23, 2021
www.prnewswire.com:443
/PRNewswire/ -- Clover Biopharmaceuticals, a global clinical-stage biotechnology company developing transformative biologics as vaccines and therapeutics for...
Clover Biopharmaceuticals
February 1, 2021
www.prnewswire.com:443
/PRNewswire/ -- Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company committed to developing transformative biologics as vaccines...
Nick Paul
December 4, 2020
FierceBiotech
Clover Biopharmaceuticals is set to start a phase 2/3 clinical trial of a COVID-19 vaccine featuring an adjuvant from GlaxoSmithKline. The Chinese vaccine developer committed to starting the study later this month after reviewing data on 150 participants in a phase 1 trial.
Cytiva
November 16, 2020
www.prnewswire.com:443
/PRNewswire/ -- Cytiva, a global life sciences leader, is supporting Clover Biopharmaceuticals, a global clinical-stage biotechnology company, to help...
June 22, 2020
Express Healthcare
Read Article Initial results from the study are expected in August GlaxoSmithKline's Covid-19 vaccine partnership with Clover Biopharmaceuticals started tests in humans, following a number of other programmes in the [...]
June 22, 2020
Clinical Trials Arena
The vaccine is based on the company's Trimer-Tag vaccine technology platform. Credit: Arek Socha from Pixabay.
MarketScreener
June 19, 2020
news.google.com
Preclinical results demonstrated the ability of CpG 1018-adjuvanted SCB-2019 to elicit neutralizing antibodies in multiple animal speciesClover expects to enroll 150 healthy adult and elderly... | June 19, 2020

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.